Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000124346 | SCV000167776 | benign | not specified | 2013-01-14 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001081685 | SCV000753935 | benign | Neuronal ceroid lipofuscinosis | 2025-02-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002316356 | SCV000851100 | benign | Inborn genetic diseases | 2016-06-27 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Athena Diagnostics | RCV000632749 | SCV001143619 | benign | not provided | 2019-05-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002483244 | SCV002796801 | likely benign | Neuronal ceroid lipofuscinosis 8 northern epilepsy variant; Neuronal ceroid lipofuscinosis 8 | 2021-10-13 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000632749 | SCV001929674 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000124346 | SCV001976179 | benign | not specified | no assertion criteria provided | clinical testing |